SavedAdd your journal

Journals / Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2022 / Cilt: 55 - Sayı: 2

Investigation of Interleukin-38 in patients with primary Sjögren’s Syndrome

Primer Sjögren Sendromlu Hastalarda İnterlökin-38 Düzeyi

Selcan GÜLTUNA
Sevinc CAN
Fevzi Nuri AYDİN
Pages
78–80
Publication Date
2022-08-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IL-38 might be relevant to the heterogeneous nature of PSS and the future role of IL-38 might be a biomarker for specific clinical manifestations of pSS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Interleukin-38 has been involved as an inflammatory mediator in rheumatic diseases.
📊
Key Findings & Data:However, little is known about the role of IL-38 in the development of primary Sjögren’s syndrome.
💡
Conclusion & Impact:IL-38 might be relevant to the heterogeneous nature of PSS and the future role of IL-38 might be a biomarker for specific clinical manifestations of pSS.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Hastalık aktivitesi · interlökin-38 · primer Sjögren sendromu

Abstract

Aim: Interleukin-38 has been involved as an inflammatory mediator in rheumatic diseases. However, little is known about the role of IL-38 in the development of primary Sjögren’s syndrome. The present study aimed to evaluate the role of IL-38 in primary Sjögren’s syndrome and its clinical relevance. Material and Method:Between 2019 and 2020, 40 patients with primary Sjögren’s syndrome and 39 healthy participants were included in the study. The serum IL-38 level was measured by ELISA in all participants. The serum levels of IL-38 were compared with clinical and laboratory features. Results:The serum IL-38 levels between the patients with primary Sjögren’s syndrome and the controls were similar (58.0 pg/ml, min-max: 0-641.0 vs. 55.0 ng/ml, min-max: 0-338.0; p=0.511). No significant correlations were found between serum IL-38 level and SSDAI (r=-0.104, p=0.523). IL-38 level was mildly negatively correlated with RF (r=-0.364, p=0.021) and positively correlated with CRP (r=0.321, p= 0.044). Conclusion:The correlation of IL-38 with CRP and RF should be considered because it might be important clues for contribution to the disease process. IL-38 might be relevant to the heterogeneous nature of PSS and the future role of IL-38 might be a biomarker for specific clinical manifestations of pSS.

Özet

Amaç: İnterlökin (IL)-38, otoimmün hastalıklarda rol oynamaktadır. Bununla birlikte, birincil Sjögren sendromunun gelişiminde IL-38'in rolü hakkında yeterli bilgi bulunmamaktadır. Bu çalışma, IL-38'in primer Sjögren sendromundaki rolünü ve klinik ilişkisini değerlendirmeyi amaçladı. Yöntemler: 2019-2020 yılları arasında primer Sjögren sendromlu 40 hasta ve 39 sağlıklı katılımcı çalışmaya dahil edildi. IL-38'in serum seviyesi, tüm katılımcılarda ELISA ile ölçüldü. IL-38'in serum seviyeleri klinik ve laboratuvar özellikleri ile karşılaştırıldı. Bulgular: Primer Sjögren sendromu hastaları ve kontrol grubu, serum IL-38 düzeyleri açısından benzerdi (58.0 pg/ml, min-maks: 0-641.0 ve 55.0 ng/ml, min-maks: 0- 338.0; p=0.511). Serum IL-38 düzeyi ile SSDAI arasında anlamlı bir ilişki bulunmadı (r=-0.104, p=0.523). IL-38 düzeyi RF ile orta derecede negatif (r=-0.364, p=0.021) ve CRP ile pozitif korelasyon (r=0.321, p= 0.044) bulundu. Sonuç: IL-38 Primer Sjögren sendromlu hastalarda CRP ve RF ile ilişkili bulunmuştur. IL-38'in gelecekteki rolü, pSS'nin spesifik klinik belirtileri için bir biyobelirteç olabilir.

🔖

Cite This Article

GÜLTUNA, S., CAN, S., AYDİN, F. N. (2022). Investigation of Interleukin-38 in patients with primary Sjögren’s Syndrome. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 55 - Sayı: 2, 78–80. https://ajindex.com/articles/712581

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Yuan X, Peng X, Li Y, et al. Role of IL-38 and its related cytokines in inflammation. Mediators of inflammation. 2015;2015
  2. Xu W-D, Su L-C, He C-S, et al. Plasma interleukin-38 in patients with rheumatoid arthritis. International immunopharmacology. 2018;65:1-7
  3. Xie L, Huang Z, Li H, Liu X, et al. IL-38: A new player in inflammatory autoimmune disorders. Biomolecules. 2019;9(8):345
  4. Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology. 2016;138(4):984-1010
  5. Xia H-s, Liu Y, Fu Y, et al. Biology of interleukin-38 and its role in chronic inflammatory diseases. International Immunopharmacology. 2021;95:107528. 6. van de Veerdonk FL, de Graaf DM, Joosten LA, et al. Biology of IL‐38 and its role in disease. Immunological reviews. 2018;281(1):191-6
  6. Xu F, Lin S, Yan X, et al. Interleukin 38 protects against lethal sepsis. The Journal of infectious diseases. 2018;218(7):1175-84
  7. Garraud T, Harel M, Boutet M-A, et al. The enigmatic role of IL-38 in inflammatory diseases. Cytokine & growth factor reviews. 2018;39:26-35
  8. Matsui K, Sano H. T helper 17 cells in primary Sjögren’s syndrome. Journal of clinical medicine. 2017;6(7):65
  9. Ciccia F, Accardo‐Palumbo A, Alessandro R, et al. Interleukin‐36α axis is modulated in patients with primary Sjögren's syndrome. Clinical & Experimental Immunology. 2015;181(2):230-8
  10. Luo D, Chen Y, Zhou N, et al. Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome. Molecular Immunology. 2020;127:107-11
  11. Vitali C, Bombardieri S, Jonsson R, et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. 2002
  12. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the rheumatic diseases. 2016;75(2):382-9
  13. Xu W-D, Huang A-F. Role of interleukin-38 in chronic inflammatory diseases: a comprehensive review. Frontiers in immunology. 2018;9:1462
  14. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in> 80 000 subjects identifies multiple loci for C